Compare Enovix Corporation (ENVX) vs Johnson & Johnson (JNJ) Price & Performance

ENVX trades at $4.73, down 2.07% today, with a bullish technical signal but bearish moving averages. Revenue growth is solid, with Q2 2026 revenue at $9.0 million, up 21% year-over-year, and consistent earnings beats. However, the company remains unprofitable, with a net income margin of -499.64% in 2026. Analyst consensus is strongly bullish, with a price target of $15.25, supported by progress in battery qualification and smart eyewear commercialization.

The outlook hinges on execution in scaling production and achieving profitability. Opportunities include expanding drone, defense, and smartphone markets, but risks are high due to cash burn, competitive pressures, and reliance on future demand. Investors face significant upside if commercialization succeeds, but losses and volatility pose substantial downside.

Johnson & Johnson (JNJ) trades at $262.08, up 0.88% with a bullish technical outlook supported by moving averages. The company demonstrates strong fundamentals with $94.19B revenue, 21.48% net margin, and consistent dividend growth spanning 64 years. Recent earnings show beats in Q1 and Q2 2026, while analysts maintain a buy consensus with a $284.50 price target representing 8.5% upside potential.

JNJ offers stable growth with defensive characteristics but faces headwinds from patent expirations and legal challenges. The stock trades at a premium valuation (P/E 30.26) but justifies it with robust profitability (ROE 25.74%). Current price near 52-week highs suggests limited near-term upside without new catalysts.